Enanta Pharmaceuticals, Inc. 9EP.F Stock
Enanta Pharmaceuticals, Inc. Price Chart
Enanta Pharmaceuticals, Inc. 9EP.F Financial and Trading Overview
| Enanta Pharmaceuticals, Inc. stock price | 11 EUR |
| Previous Close | 21.6 EUR |
| Open | 22 EUR |
| Bid | 21.8 EUR x 15600 |
| Ask | 22.2 EUR x 15300 |
| Day's Range | 22 - 22 EUR |
| 52 Week Range | 21.2 - 72.5 EUR |
| Volume | 60 EUR |
| Avg. Volume | 1 EUR |
| Market Cap | 477.5M EUR |
| Beta (5Y Monthly) | 0.384859 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.75 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 65.33 EUR |
9EP.F Valuation Measures
| Enterprise Value | 269.92M EUR |
| Trailing P/E | N/A |
| Forward P/E | -4.007286 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 5.8823223 |
| Price/Book (mrq) | 1.7190186 |
| Enterprise Value/Revenue | 3.325 |
| Enterprise Value/EBITDA | -2.132 |
Trading Information
Enanta Pharmaceuticals, Inc. Stock Price History
| Beta (5Y Monthly) | 0.384859 |
| 52-Week Change | -44.55% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 72.5 EUR |
| 52 Week Low | 21.2 EUR |
| 50-Day Moving Average | 28.96 EUR |
| 200-Day Moving Average | 42.53 EUR |
9EP.F Share Statistics
| Avg. Volume (3 month) | 1 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 21.06M |
| Float | 16.09M |
| Short Ratio | N/A |
| % Held by Insiders | 6.59% |
| % Held by Institutions | 93.65% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | September 30, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | September 30, 2023 |
Profitability
| Profit Margin | -153.60% |
| Operating Margin (ttm) | -158.97% |
| Gross Margin | 100.00% |
| EBITDA Margin | -155.99% |
Management Effectiveness
| Return on Assets (ttm) | -22.00000000000000000000000000000000% |
| Return on Equity (ttm) | -39.71% |
Income Statement
| Revenue (ttm) | 81.18M EUR |
| Revenue Per Share (ttm) | 3.9 EUR |
| Quarterly Revenue Growth (yoy) | -4.90% |
| Gross Profit (ttm) | 86.16M EUR |
| EBITDA | -126630000 EUR |
| Net Income Avi to Common (ttm) | -124692000 EUR |
| Diluted EPS (ttm) | -5.1 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 210.08M EUR |
| Total Cash Per Share (mrq) | 9.98 EUR |
| Total Debt (mrq) | 29.42M EUR |
| Total Debt/Equity (mrq) | 10.92 EUR |
| Current Ratio (mrq) | 8.429 |
| Book Value Per Share (mrq) | 12.798 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -94560000 EUR |
| Levered Free Cash Flow (ttm) | -56517500 EUR |
Profile of Enanta Pharmaceuticals, Inc.
| Country | Germany |
| State | MA |
| City | Watertown |
| Address | 500 Arsenal Street |
| ZIP | 02472 |
| Phone | 617 607 0800 |
| Website | https://www.enanta.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 160 |
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Q&A For Enanta Pharmaceuticals, Inc. Stock
What is a current 9EP.F stock price?
Enanta Pharmaceuticals, Inc. 9EP.F stock price today per share is 11 EUR.
How to purchase Enanta Pharmaceuticals, Inc. stock?
You can buy 9EP.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Enanta Pharmaceuticals, Inc.?
The stock symbol or ticker of Enanta Pharmaceuticals, Inc. is 9EP.F.
Which industry does the Enanta Pharmaceuticals, Inc. company belong to?
The Enanta Pharmaceuticals, Inc. industry is Biotechnology.
How many shares does Enanta Pharmaceuticals, Inc. have in circulation?
The max supply of Enanta Pharmaceuticals, Inc. shares is 21.49M.
What is Enanta Pharmaceuticals, Inc. Price to Earnings Ratio (PE Ratio)?
Enanta Pharmaceuticals, Inc. PE Ratio is now.
What was Enanta Pharmaceuticals, Inc. earnings per share over the trailing 12 months (TTM)?
Enanta Pharmaceuticals, Inc. EPS is -5.75 EUR over the trailing 12 months.
Which sector does the Enanta Pharmaceuticals, Inc. company belong to?
The Enanta Pharmaceuticals, Inc. sector is Healthcare.